HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
KP 10614
structure given in first source
Also Known As:
4,5,18,18,19,19-hexadehydro-16,20-dimethyl-delta 6(9a)-9(O)-methano-prostaglandin I1; KP-10614
Networked:
3
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Lipids: 114793
Fatty Acids: 27405
Unsaturated Fatty Acids: 8236
Eicosanoids: 3262
Prostaglandins: 17100
Prostaglandins I: 108
Epoprostenol: 4670
KP 10614: 3
Biological Factors: 2472
Inflammation Mediators: 1113
Autacoids: 276
Eicosanoids: 3262
Prostaglandins: 17100
Prostaglandins I: 108
Epoprostenol: 4670
KP 10614: 3
Related Diseases
1.
Myocardial Infarction
07/01/1993 - "
These data supported the hypothesis that KP-10614, a new prostacyclin analog, had protective effects on myocardial infarction in rats by suppressing the platelet-polymorphonuclear leukocyte interaction at the site of tissue injury in vivo.
"
10/01/1992 - "
Beneficial effects of a new prostacyclin analogue, KP-10614, on acute myocardial infarction in rats.
"
2.
Infarction (Infarctions)
10/01/1992 - "
These results suggest that platelets play an important role in expression of myocardial ischemic injury resulting from coronary artery occlusion in rats, and the ability of KP-10614 to decrease the infarct size appeared to be attributable, at least in part, to the inhibition of platelet aggregation or cellular metabolic effects produced by platelets at the site of tissue injury.
"
10/01/1992 - "
KP-10614 (3 ng/kg/min x 4 h) reduced the infarct size at 4 h significantly (26.5 +/- 2.9%).
"
07/01/1993 - "
We have reported that KP-10614, infused i.v. at a dose of 3 ng/kg/min for 4 hr, inhibited platelet functions and reduced the experimental cardiac infarct size significantly, but did not change hemodynamic parameters and the ischemic area of the heart induced by ligation of the left descending coronary artery in rats.
"
07/01/1993 - "
A new prostacyclin analog, KP-10614, inhibits platelet-polymorphonuclear leukocyte interaction and limits experimental infarct size in rat heart.
"
3.
Thrombosis (Thrombus)
12/01/1990 - "
In addition, KP-10614 showed definite antithrombotic effects at a dose range of 0.1 to 1 microgram/kg i.v. in various thrombosis models in which platelet aggregation was mainly involved.
"
Related Drugs and Biologics
1.
Epoprostenol (Prostacyclin)
Related Therapies and Procedures
1.
Ligation